Nitric oxide in the pathophysiology of myocardial dysfunction in heart failure;O óxido nítrico na fisiopatologia da disfunção miocárdica na insuficiência cardíaca

Revista Portuguesa de Cardiologia

Volumn 23, Issue SUPPL. 2, 2004, Pages

  Brás Silva, Carmen ^a   Leite Moreira, Adelino F ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Heart failure; Myocardial function; Nitric oxide; Nitric oxide synthases

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUROHORMONE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; AUTOCRINE EFFECT; CORONARY ARTERY DILATATION; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ENZYME ACTIVATION; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE VARIABILITY; HUMAN; MITOCHONDRIAL RESPIRATION; MOLECULAR BIOLOGY; MYOCARDIAL DISEASE; PARACRINE SIGNALING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE;

HEART; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 3142777062     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
3. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res 1988;62: 358-66.
4. Smith JA, Shah AM, Lewis MJ. Factors released from endocardium of the ferret and pig modulate myocardial contraction. J Physiol 1991;439:1-14.
5. Li K, Rouleau JL, Andries LJ, Brutsaert DL. Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ Res 1993;72:768-77.
6. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999;43:521-31.
7. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-7.
8. Mungrue IN, Husain M, Stewart DJ. The role of NOS in heart failure: lessons from murine genetic models. Heart Fail Rev 2002;7:407-22.
9. Forstermann U, Closs EI, Pollock JS, e col. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121-31.
10. Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 1997;22: 477-81.
11. Klimaschewski L, Kummer W, Mayer B, e col. Nitric oxide synthase in cardiac nerve fibers and neurons of rat and guinea pig heart. Circ Res 1992;71:1533-7.
12. Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 1995; 77:841-8.
13. Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 1999;96:657-62.
14. Schulz R, Smith JA, Lewis MJ, Moncada S. Nitric oxide synthase in cultured endocardial cells of the pig. Br J Pharmacol 1991;104:21-4.
15. Balligand JL, Kobzik L, Han X, e col. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 1995;270:14582-6.
16. Han X, Shimoni Y, Giles WR. A cellular mechanism for nitric oxide-mediated cholinergic control of mammalian heart rate. J Gen Physiol 1995;106:45-65.
17. Han X, Kobzik L, Balligand JL, Kelly RA, Smith TW. Nitric oxide synthase (NOS3)-mediated cholinergic modulation of Ca2+ current in adult rabbit atrioventricular nodal cells. Circ Res 1996;78:998-1008.
18. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca(2+)-independent nitric oxide svnthase in the myocardium. Br J Pharmacol 1992;105: 575-80.
19. Smith JA, Radomski MW, Schulz R, Moncada S, Lewis MJ. Porcine ventricular endocardial cells in culture express the inducible form of nitric oxide synthase. Br J Pharmacol 1993;108:1107-10.
20. Shindo T, Ikeda U, Ohkawa F, e col. Nitric oxide synthesis in rat cardiac myocytes and fibroblasts. Life Sci 1994;55: 1101-8.
21. Balligand JL, Ungureanu-Longrois D, Simmons WW, e col. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 1994;269:27580-8.
22. Balligand JL, Ungureanu-Longrois D, Simmons WW, e col. Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1 beta and IFN-gamma. Am J Physiol 1995;268:H1293-303.
23. Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol 1995;269:H550-5.
24. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1995;15:1255-61.
25. Goetz RM, Morano I, Calovini T, Studer R, Holtz J. Increased expression of endothelial constitutive nitric oxide synthase in rat aorta during pregnancy. Biochem Biophys Res Commun 1994;205:905-10.
26. Zembowicz A, Tang JL, Wu KK. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem 1995;270:17006-10.
27. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995;76:958-62.
28. Ravichandran LV, Johns RA. Up-regulation of endothelial nitric oxide synthase expression by cyclic guanosine 3′,5′-monophosphate. FEBS Lett 1995;374:295-8.
29. Arnal JF, Yamin J, Dockery S, Harrison DG. Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. Am J Physiol 1994;267:C1381-8.
30. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.
31. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74:349-53.
32. Hare JM, Kim B, Flavahan NA, e col. Pertussis toxin-sensitive G proteins influence nitric oxide synthase III activity and protein levels in rat heart. J Clin Invest 1998;101: 1424-31.
33. Belhassen L, Kelly RA, Smith TW, Balligand JL. Nitric oxide synthase (NOS3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart. Regulation of NOS3 transcription in vitro and in vivo by cyclic adenosine monophosphate in rat cardiac myocytes. J Clin Invest 1996;97:1908-15.
34. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73:205-9.
35. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-24.
36. McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994;267:H1921-7.
37. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res 1999;43:532-41.
38. Papapetropoulos A, Rudic RD, Sessa WC Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res 1999;43:509-20.
39. Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K. Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation 1995;92: 2683-9.
40. Ikeda U, Murakami Y, Kanbe T, Shimada K. Alpha-adrenergic stimulation enhances inducible nitric oxide synthase expression in rat cardiac myocytes. J Mol Cell Cardiol 1996;28:1539-45.
41. Ikeda U, Kanbe T, Kawahara Y, Yokoyama M, Shimada K. Adrenomedullin augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Circulation 1996;94:2560-5.
42. Ikeda U, Yamamoto K, Ichida M, e col. Cyclic AMP augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. J Mol Cell Cardiol 1996;28:789-95.
43. Yamamoto K, Ikeda U, Okada K, e col. Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. Hypertension 1997;30:1112-20.
44. Nuedling S, Kahlert S, Loebbert K, e col. 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res 1999;43:666-74.
45. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. J Biol Chem 1995;270:28471-8.
46. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 2000;86:49-86.
47. Simmons WW, Closs EI, Cunningham JM, Smith TW, Kelly RA. Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. Regulation of L-arginine transport and no production by CAT-1, CAT-2A, and CAT-2B. J Biol Chem 1996;271:11694-702.
48. Buga GM, Singh R, Pervin S, e col. Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996;271:H1988-98.
49. Papapetropoulos A, Desai KM, Rudic RD, e col Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol 1997;150:1835-44.
50. Papadaki M, Tilton RG, Eskin SG, McIntire LV. Nitric oxide production by cultured human aortic smooth muscle cells: stimulation by fluid flow. Am J Physiol 1998;274: H616-26.
51. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43:542-8.
52. Trochu JN, Bouhour JB, Kaley G, Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 2000;87:1108-17.
53. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J 1993;7:328-38.
54. Hove-Madsen L, Mery PF, Jurevicius J, Skeberdis AV, Fischmeister R. Regulation of myocardial calcium channels by cyclic AMP metabolism. Basic Res Cardiol 1996;91 Suppl 2:1-8.
55. Mery PF, Abi-Gerges N, Vandecasteele G, Jurevicius J, Eschenhagen T, Fischmeister R. Muscarinic regulation of the L-type calcium current in isolated cardiac myocytes. Life Sci 1997;60(13-14):1113-20.
56. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999;84:1020-31.
57. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996;271:C1424-37.
58. Nossuli TO, Hayward R, Scalia R, Lefer AM. Peroxynitrite reduces myocardial infarct size and preserves coronary endothelium after ischemia and reperfusion in cats. Circulation 1997;96:2317-24.
59. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
60. Eiserich JP, Hristova M, Cross CE, e col. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998;391:393-7.
61. Sarkar D, Vallance P, Amirmansour C, Harding SE. Positive inotropic effects of NO donors in isolated guinea-pig and human cardiomyocytes independent of NO species and cyclic nucleotides. Cardiovasc Res 2000;48:430-9.
62. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 1993;90:347-51.
63. Mery PF, Pavoine C, Belhassen L, Pecker F, Fischmeister R. Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 1993;268:26286-95.
64. Sandirasegarane L, Diamond J. The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independent of cyclic GMP elevation. J Mol Cell Cardiol 1999;31:799-808.
65. Mohan P, Brutsaert DL, Paulus WJ, Sys SU. Myocardial contractile response to nitric oxide and cGMP. Circulation 1996;93:1223-9.
66. Kojda G, Kottenberg K, Nix P, Schluter KD, Piper HM, Noack E. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 1996;78:91-101.
67. Kirstein M, Rivet-Bastide M, Hatem S, Benardeau A, Mercadier JJ, Fischmeister R. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest 1995;95:794-802.
68. Preckel B, Kojda G, Schlack W, e col. Inotropic effects of glyceryl trinitrate and spontaneous NO donors in the dog heart. Circulation 1997;96:2675-82.
69. Cotton JM, Kearney MT, MacCarthy PA, e col. Effects of nitric oxide synthase inhibition on Basal function and the force-frequency relationship in the normal and failing human heart in vivo. Circulation 2001;104:2318-23.
70. Campbell DL, Stamler JS, Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 1996;108:277-93.
71. Stoyanovsky D, Murphy T, Anno PR, Kim YM, Salama G. Nitric oxide activates skeletal and cardiac ryanodine receptors. Cell Calcium 1997;21:19-29.
72. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 1998;279:234-7.
73. Chesnais JM, Fischmeister R, Mery PF. Positive and negative inotropic effects of NO donors in atrial and ventricular fibres of the frog heart. J Physiol 1999;518:449-61.
74. Paolocci N, Ekelund UE, Isoda T, e col. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ Physiol 2000;279:H1982-8.
75. Brady AJ, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993;265:H176-82.
76. Grocott-Mason R, Fort S, Lewis MJ, Shah AM. Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol 1994;266:H1699-705.
77. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994;89:2070-8.
78. Flesch M, Kilter H, Cremers B, e col. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther 1997;281:1340-9.
79. Layland J, Li JM, Shah AM. Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol 2002;540: 457-67.
80. Ito N, Bartunek J, Spitzer KW, Lorell BH. Effects of the nitric oxide donor sodium nitroprusside on intracellular pH and contraction in hypertrophied myocytes. Circulation 1997;95:2303-11.
81. Brunner F, Andrew P, Wolkart G, Zechner R, Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001;104:3097-102.
82. Kelm M, Schafer S, Dahmann R, e col. Nitric oxide induced contractile dysfunction is related to a reduction in mvocardial energy generation. Cardiovasc Res 1997;36: 185-94.
83. Decking UK, Williams JP, Dahmann R, Stumpe T, Kelm M, Schrader J. The nitric oxide-induced reduction in cardiac energy supply is not due to inhibition of creatine kinase. Cardiovasc Res 2001;51:313-21.
84. Finkel MS, Oddis CV, Mayer OH, Hattler BG, Simmons RL. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship. J Pharmacol Exp Ther 1995;272:945-52.
85. Kaye DM, Wiviott SD, Balligand JL, Simmons WW, Smith TW, Kelly RA. Frequency-dependent activation of a constitutive nitric oxide synthase and regulation of contractile function in adult rat ventricular myocytes. Circ Res 1996;78:217-24.
86. Kaye DM, Wiviott SD, Kelly RA. Activation of nitric oxide synthase (NOS3) by mechanical activity alters contractile activity in a Ca2+-independent manner in cardiac myocytes: role of troponin I phosphorylation. Biochem Biophys Res Commun 1999;256:398-403.
87. Paulus WJ, Bronzwaer JG. Myocardial contractile effects of nitric oxide. Heart Fail Rev 2002;7:371-83.
88. Keaney JF Jr, Hare JM, Balligand JL, Loscalzo J, Smith TW, Colucci WS. Inhibition of nitric oxide synthase augments myocardial contractile responses to beta-adrenergic stimulation. Am J Physiol 1996;271:H2646-52.
89. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary endothelial control of left ventricular function in humans. Circulation 1995;92:2119-26.
90. Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG. 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. Circ Res 1994;74:970-8.
91. Pinsky DJ, Patton S, Mesaros S, e col. Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res 1997;81:372-9.
92. Prendergast BD, Sagach VF, Shah AM. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation 1997;96:1320-9.
93. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res 1999;43:595-606.
94. Sears CE, Bryant SM, Ashley EA, e col. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 2003;92:e52-9.
95. Paton JF, Kasparov S, Paterson DJ. Nitric oxide and autonomic control of heart rate: a question of specificity. Trends Neurosci 2002;25:626-31.
96. Chen RY, Fan FC, Schuessler GB, Chien S. Baroreflex control of heart rate in humans during nitroprusside-induced hypotension. Am J Physiol 1982;243:R18-R24.
97. Tassorelli C, Joseph SA, Buzzi MG, Nappi G. The effects on the central nervous system of nitroglycerin-putative mechanisms and mediators. Prog Neurobiol 1999;57:607-24.
98. Armour JA, Smith FM, Losier AM, Ellenberger HH, Hopkins DA. Modulation of intrinsic cardiac neuronal activity by nitric oxide donors induces cardiodynamic changes. Am J Physiol 1995;268:R403-13.
99. Hogan N, Casadei B, Paterson DJ. Nitric oxide donors can increase heart rate independent of autonomic activation. J Appl Physiol 1999;87:97-103.
100. Chowdhary S, Harrington D, Bonser RS, Coote JH, Townend JN. Chronotropic effects of nitric oxide in the denervated human heart. J Physiol 2002;541:645-51.
101. Herring N, Rigg L, Terrar DA, Paterson DJ. NO-cGMP pathway increases the hyperpolarisation-activated current, I(f), and heart rate during adrenergic stimulation. Cardiovasc Res 2001;52:446-53.
102. Musialek P, Lei M, Brown HF, Paterson DJ, Casadei B. Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current, I(f). Circ Res 1997;81:60-8.
103. Choate JK, Paterson DJ. Nitric oxide inhibits the positive chronotropic and inotropic responses to sympathetic nerve stimulation in the isolated guinea-pig atria. J Auton Nerv Syst 1999;75:100-8.
104. Elvan A, Rubart M, Zipes DP. NO modulates autonomic effects on sinus discharge rate and AV nodal conduction in open-chest dogs. Am J Physiol 1997;272:H263-71.
105. Herring N, Paterson DJ. Nitric oxide-cGMP pathway facilitates acetylcholine release and bradycardia during vagal nerve stimulation in the guinea-pig in vitro. J Physiol 2001; 535:507-18.
106. Choate JK, Danson EJ, Morris JF, Paterson DJ. Peripheral vagal control of heart rate is impaired in neuronal NOS knockout mice. Am J Physiol Heart Circ Physiol 2001; 281:H2310-7.
107. Markos F, Snow HM, Kidd C, Conlon K. Nitric oxide facilitates vagal control of heart rate via actions in the cardiac parasympathetic ganglia of the anaesthetised dog. Exp Physiol 2002;87:49-52.
108. Conlon K, Kidd C. Neuronal nitric oxide facilitates vagal chronotropic and dromotropic actions on the heart. J Auton Nerv Syst 1999;75:136-46.
109. Han X, Shimoni Y, Giles WR. An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J Physiol 1994;476:309-14.
110. Recchia FA, McConnell PI, Loke KE, Xu X, Ochoa M, Hintze TH. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 1999;44:325-32.
111. Smith CJ, Sun D, Hoegler C, e col. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996;78:58-64.
112. Mohri M, Egashira K, Tagawa T, e col. Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure. Hypertension 1997;30:50-6.
113. Arimura K, Egashira K, Nakamura R, e col. Increased inactivation of nitric oxide is involved in coronary endothelial dysfunction in heart failure. Am J Physiol Heart Circ Physiol 2001;280:H68-75.
114. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 2001;41:203-36.
115. Zhang XP, Tada H, Wang Z, Hintze TH. cAMP signal transduction, a potential compensatory pathway for coronary endothelial NO production after heart failure. Arterioscler Thromb Vasc Biol 2002;22:1273-8.
116. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998;83:969-79.
117. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998;32:955-63.
118. O'Murchu B, Miller VM, Perrella MA, Burnett JC Jr. Increased production of nitric oxide in coronary arteries during congestive heart failure. J Clin Invest 1994;93:165-71.
119. Fukuchi M, Hussain SN, Giaid A. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure: their relation to lesion site and beta-adrenergic receptor therapy. Circulation 1998;98:132-9.
120. Stein B, Eschenhagen T, Rudiger J, Scholz H, Forstermann U, Gath I. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. J Am Coll Cardiol 1998;32:1179-86.
121. Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, Paulus WJ. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999;99:3009-16.
122. Kaye DM, Parnell MM, Ahlers BA. Reduced myocardial and systemic L-arginine uptake in heart failure. Circ Res 2002;91:1198-203.
123. Feng Q, Lu X, Fortin AJ, e col. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 1998;37:667-75.
124. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998;62:2425-30.
125. Nakamura R, Egashira K, Arimura K, e col. Increased inactivation of nitric oxide is involved in impaired coronary flow reserve in heart failure. Am J Physiol Heart Circ Physiol 2001;281:H2619-25.
126. Landmesser U, Spiekermann S, Dikalov S, e col. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002;106: 3073-8.
127. Agnoletti L, Curello S, Bachetti T, e col. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 1999;100:1983-91.
128. Li D, Tomson K, Yang B, Mehta P, Croker BP, Mehta JL. Modulation of constitutive nitric oxide synthase, bcl-2 and Fas expression in cultured human coronary endothelial cells exposed to anoxia-reoxygenation and angiotensin II: role of AT1 receptor activation. Cardiovasc Res 1999;41: 109-15.
129. De Gasparo M. Angiotensin II and Nitric Oxide Interaction. Heart Fail Rev 2002;7:347-58.
130. De Belder AJ, Radomski MW, Why HJ, e col. Nitric oxide synthase activities in human myocardium. Lancet 1993;341:84-5.
131. Haywood GA, Tsao PS, von der Leyen HE, e col. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-94.
132. Harding SE, Davies CH, Money-Kyrle AM, Poole-Wilson PA. An inhibitor of nitric oxide synthase does not inerease contraction or beta-adrenoceptor sensitivity of ventricular myocytes from failing human heart. Cardiovasc Res 1998;40: 523-9.
133. Paulus WJ, Kastner S, Vanderheyden M, Shah AM, Drexler H. Myocardial contractile effects of L-arginine in the human allograft. J Am Coll Cardiol 1997;29:1332-8.
134. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Circ Res 1996;79:381-7.
135. Recchia FA. Role of nitric oxide in the regulation of substrate metabolism in heart failure. Heart Fail Rev 2002;7:141-8.
136. Wollert KC e Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002;7:317-25.
137. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102(20 Suppl 4):IV14-23.
138. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101: 812-8.
139. Yamamoto T, Bing RJ. Nitric oxide donors. Proc Soc Exp Biol Med 2000;225:200-6.
140. Mason DT, Braunwald E. The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation 1965;32:755-66.
141. Wiemer G, Scholkens BA, Becker RH, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-63.
142. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
143. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104: 1856-62.
144. Kitakaze M, Asanuma H, Funaya H, e col. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol 2002;40:162-6.
145. McLay JS, Chatterjee PK, Jardine AG, Hawksworth GM. Atrial natriuretic factor modulates nitric oxide production: an ANF-C receptor-mediated effect. J Hypertens 1995;13:625-30.
146. Costa MD, Bosc LV, Majowicz MP, Vidal NA, Balaszczuk AM, Arranz CT. Atrial natriuretic peptide modifies arterial blood pressure through nitric oxide pathway in rats. Hypertension 2000;35:1119-23.
147. Brunner F, Wolkart G. Endothelial NO/cGMP system contributes to natriuretic peptide-mediated coronary and peripheral vasodilation. Microvasc Res 2001;61:102-10.
148. Calderone A. The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases. Heart Fail Rev 2003;8: 55-70.
149. Trippodo NC, Panchal BC, Fox M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 1995;272:619-27.
150. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36:479-86.
151. Rouleau JL, Pfeffer MA, Stewart DJ, e col. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20.
152. Packer M, O'Connor CM, Ghali JK, e col. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-14.
153. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998;97:576-80.
154. Zhang X, Kichuk MR, Mital S e col. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am J Cardiol 1999;84:27L-33L.
155. Nakamura M, Arakawa N, Yoshida H, Naganuma Y, Nagano M, Hiramori K. Nitric oxide plays an insignificant role in direct vasodilator effects of calcium channel blockers in healthy humans. Heart Vessels 2002;16:105-10.
156. Wang WZ, Matsumori A, Yamada T, e col. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation 1997;95:245-51.
157. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 1995;269:C750-6.
158. Wildhirt SM, Suzuki H, Wolf WP, e col. S-methylisothiourea inhibits inducible nitric oxide synthase and improves left ventricular performance after acute myocardial infarction. Biochem Biophys Res Commun 1996;227:328-33.
159. Wildhirt SM, Schulze C, Conrad N, Kornberg A, Horstman D, Reichart B. Aminoguanidine inhibits inducible NOS and reverses cardiac dysfunction late after ischemia and reperfusion-implications for iNOS-mediated myocardial stunning. Thorac Cardiovasc Surg 1999;47:137-43.
160. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 1998;97:161-6.
161. Mostafa AM, Nagi MN, Al Rikabi AC, Al-Shabanah OA, El-Kashef HA. Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicin treatment in rats. Res Commun Mol Pathol Pharmacol 1999;106: 193-202.
162. Kobayashi N, Horinaka S, Mita S, e col. Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in failing hearts of salt-sensitive hypertensive rats. J Hypertens 2002;20:2475-85.
163. Saito T, Hu F, Tayara L, Fahas L, Shennib H, Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 2002;283:H339-45.
164. Bocchi EA, Vilella de Moraes AV, Esteves-Filho A, e col. L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin Cardiol 2000;23:205-10.
165. Hambrecht R, Hilbrich L, Erbs S, e col. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000;35:706-13.
166. Maxwell AJ e Cooke JP. Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens 1998;7:63-70.
167. Setoguchi S, Hirooka Y, Eshima K, Shimokawa H, Takeshita A. Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure. J Cardiovasc Pharmacol 2002;39:363-8.
168. Huang A, Vita JA, Venema RC, Keaney JF Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000;275(23):17399-406.
169. Bates K, Ruggeroli CE, Goldman S, Gaballa MA. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol 2002;283:H768-75.
170. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-41.
171. Molinau H, Meinertz T, Hink U, Muenzel T. HMG-CoA reductase inhibition inhibits vascular NADH oxidase activity, prevents uncoupling of nitric oxide synthase and improves endothelial dysfunction in colesterol fed rabbits (abstract). European Heart J 2000;21:16.
172. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
173. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-8.
174. Flogel U, Merx MW, Godecke A, Decking UK, Schrader J. Myoglobin: A scavenger of bioactive NO. Proc Natl Acad Sci USA 2001;98:735-40.
175. Katz SD. Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Congest Heart Fail 2003;9:9-15.
176. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, e col. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003;107:686-9.
177. Jones SP, Greer JJ, Van Haperen R, Duncker DJ, De Crom R, Lefer DJ. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 2003;100:4891-6.